fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Tesla’s Makes Its Model Y In China Costlier After Recent Price Cuts – $TSLA $SPY $INVO

By John F. Heerdink, Jr.

Reportedly, Tesla Inc. (TSLA) has raised the beginning price of its Model Y crossovers by .8% to 261,900 yuan ($38,577.11) in China raising the price for the rear-wheel drive version of Model Y by 2,000 yuan from 259,900 yuan previously. The company planned to boost output at its Shanghai plant over the next 2 months to meet the increasing demand driven by aggressive price cuts on its best-selling models. The prices for other versions of Model Y and the Model 3 cars remain unchanged. 

Visit the VP Watchlist to learn more about Tesla (TSLA)Apple (AAPL), and other companies highlighted in our targeted list.  
 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.



DID YOU KNOW?

Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market


(Read Original Story: UPDATE 1-Tesla, after recent cuts, raises starting price of Model Y in China in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us